Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Response of Umeclidinium in COPD
NCT01372410Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2011
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by GSK. Primary endpoints: Trough Forced Expiratory Volume in One Second at Day 8, Trough FEV1 for ED50 (Potency) Parameter at Day 8 and 1 more. Started Jul 2011; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01372410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01372410.